Clinical trial
Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With…
NCT00225992 · Oncology Specialties, Alabama, Other · Terminated
Key facts
| NCT number | NCT00225992 |
|---|---|
| Title | Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) |
| Official title | A Phase II Research Study of Arsenic Trioxide (Trisenox) in Patients With Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Oncology Specialties, Alabama, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome (MDS) |
| Intervention type | Drug |
| Interventions | Arsenic Trioxide |
| Start date | Feb 1, 2004 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Sep 26, 2005 |
| Last update posted | Oct 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: